JP2011516565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516565A5 JP2011516565A5 JP2011504152A JP2011504152A JP2011516565A5 JP 2011516565 A5 JP2011516565 A5 JP 2011516565A5 JP 2011504152 A JP2011504152 A JP 2011504152A JP 2011504152 A JP2011504152 A JP 2011504152A JP 2011516565 A5 JP2011516565 A5 JP 2011516565A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- stilbene
- agent
- trimethoxy
- angiogenesis inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4396408P | 2008-04-10 | 2008-04-10 | |
| US61/043,964 | 2008-04-10 | ||
| PCT/US2009/039899 WO2009126705A2 (en) | 2008-04-10 | 2009-04-08 | Induction of tumor hypoxia for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015001834A Division JP5944018B2 (ja) | 2008-04-10 | 2015-01-07 | 癌治療用腫瘍低酸素の誘発 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011516565A JP2011516565A (ja) | 2011-05-26 |
| JP2011516565A5 true JP2011516565A5 (enExample) | 2012-04-05 |
| JP5731372B2 JP5731372B2 (ja) | 2015-06-10 |
Family
ID=41162569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011504152A Active JP5731372B2 (ja) | 2008-04-10 | 2009-04-08 | 癌治療用腫瘍低酸素の誘発 |
| JP2015001834A Active JP5944018B2 (ja) | 2008-04-10 | 2015-01-07 | 癌治療用腫瘍低酸素の誘発 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015001834A Active JP5944018B2 (ja) | 2008-04-10 | 2015-01-07 | 癌治療用腫瘍低酸素の誘発 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8591921B2 (enExample) |
| JP (2) | JP5731372B2 (enExample) |
| KR (1) | KR101925436B1 (enExample) |
| CN (2) | CN102026634B (enExample) |
| TW (1) | TWI504391B (enExample) |
| WO (1) | WO2009126705A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2592103Y2 (ja) | 1992-07-23 | 1999-03-17 | 東海旅客鉄道株式会社 | ケーブルトラフ |
| DK1896040T3 (da) | 2005-06-29 | 2012-09-03 | Threshold Pharmaceuticals Inc | Phosphoramidat-alkylator-prodrugs |
| KR101925436B1 (ko) | 2008-04-10 | 2018-12-05 | 버지니아 커먼웰스 유니버시티 | 암 치료를 위한 종양 저 산소 상태의 유도 |
| WO2012009288A2 (en) * | 2010-07-12 | 2012-01-19 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| EP2407161A1 (en) * | 2010-07-13 | 2012-01-18 | Sanofi | An antitumoral combination comprising ombrabulin and bevacizumab |
| WO2012145684A1 (en) | 2011-04-22 | 2012-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Transient hypoxia inducers and their use |
| WO2013096687A1 (en) | 2011-12-22 | 2013-06-27 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer |
| CN102512692B (zh) * | 2012-01-16 | 2014-07-16 | 北京大学 | 肿瘤靶向栓塞治疗组合物及其制备方法 |
| AU2013204313C1 (en) | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
| WO2015069489A1 (en) | 2013-11-06 | 2015-05-14 | Merck Patent Gmbh | Predictive biomarker for hypoxia-activated prodrug therapy |
| CA2930001A1 (en) * | 2013-11-11 | 2015-05-14 | University Hospitals Cleveland Medical Center | Targeted treatment of anerobic cancer |
| US9586056B2 (en) * | 2014-07-03 | 2017-03-07 | Haniva Llc | Combination therapy for treating cancer and method for treating cancer using a combination therapy |
| EP3177713B1 (en) * | 2014-08-08 | 2020-08-05 | Poseida Therapeutics, Inc. | Compositions and their use for inducing nanoparticle-mediated microvascular embolization of tumors |
| EP4548978A3 (en) | 2015-01-29 | 2025-08-06 | Oxyrase, Inc. | Methods for inhibiting tumor growth |
| EP3294313A4 (en) * | 2015-05-15 | 2019-04-17 | The General Hospital Corporation | METHODS RELATING TO THE PREVENTION AND TREATMENT OF DRUG RESISTANCE |
| US10456452B2 (en) | 2015-07-02 | 2019-10-29 | Poseida Therapeutics, Inc. | Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles |
| IL258701B2 (en) | 2015-10-21 | 2024-07-01 | Teclison Ltd | Preparations and methods for curing cancer with immune support |
| ES2865481T3 (es) | 2016-04-29 | 2021-10-15 | Poseida Therapeutics Inc | Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos |
| CN108348463A (zh) * | 2016-05-13 | 2018-07-31 | 泰克利森有限公司 | 用于治疗肝脏组织的方法 |
| CN107007571B (zh) * | 2017-02-24 | 2020-08-21 | 福州市传染病医院 | 肿瘤微酸性敏感的铜-药物共配位自组装纳米粒及应用 |
| CN110051848A (zh) * | 2019-05-06 | 2019-07-26 | 中国科学院长春应用化学研究所 | 药物组合、应用以及抗肿瘤的药物 |
| CN110585214A (zh) * | 2019-09-25 | 2019-12-20 | 湖北大学 | 一种促进治疗肿瘤效果的纳米粒子及其合成方法 |
| CN110713596B (zh) * | 2019-11-08 | 2022-04-29 | 西北师范大学 | 肿瘤无导管栓塞用pH-还原双响应高分子栓塞剂及其合成 |
| CN112961082B (zh) * | 2021-02-22 | 2022-09-06 | 沈阳药科大学 | 一种血管阻断剂与双载药仿生脂质体联用的给药系统 |
| JP7730130B2 (ja) * | 2021-03-02 | 2025-08-27 | ドリームメディカルパートナーズ株式会社 | 塞栓材及びその製造方法 |
| AU2022350496A1 (en) * | 2021-09-22 | 2024-04-04 | Board Of Regents, The University Of Texas System | Quantitative magnetic resonance imaging and tumor forecasting |
| CN114344482B (zh) * | 2022-01-14 | 2023-05-12 | 重庆医科大学附属第二医院 | 一种基于金属有机骨架的多功能纳米粒及其制备方法与应用 |
| WO2024006901A1 (en) * | 2022-06-29 | 2024-01-04 | Diffusion Pharmaceuticals Llc | Uses of bipolar trans carotenoids in the treatment of cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3980779A (en) | 1972-02-01 | 1976-09-14 | Bayer Aktiengesellschaft | 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same |
| US5175287A (en) | 1986-09-25 | 1992-12-29 | S R I International | Process for preparing 1,2,4-benzotriazine oxides |
| US5616584A (en) | 1986-09-25 | 1997-04-01 | Sri International | 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents |
| DE69114782T2 (de) * | 1990-08-08 | 1996-04-18 | Takeda Chemical Industries Ltd | Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff. |
| DK0797988T3 (da) | 1993-07-19 | 2009-05-11 | Univ British Columbia | Anti-angiogene præparater og fremgangsmåder til anvendelse deraf |
| US5484612A (en) | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| GB9404400D0 (en) | 1994-03-07 | 1994-04-20 | Wood Pauline J | Potentiation of bioreductive agents |
| EP1014990B1 (en) | 1997-03-07 | 2006-09-06 | Sanofi-Aventis U.S. LLC | Antitumor combination of 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum |
| DE10012120A1 (de) | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
| WO2003022248A1 (en) * | 2001-09-13 | 2003-03-20 | Korea Institute Of Science And Technology | Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| WO2004064734A2 (en) * | 2003-01-17 | 2004-08-05 | Threshold Pharmaceuticals, Inc. | Combination therapies for the treatment of cancer |
| ATE366579T1 (de) | 2003-02-26 | 2007-08-15 | Nerviano Medical Sciences Srl | Verfahren zur behandlung von leberkrebs durch intrahepatische verabreichung von nemorubicin |
| ITRM20030355A1 (it) | 2003-07-18 | 2005-01-19 | Sigma Tau Ind Farmaceuti | Composti ad attivita' citotossica derivati della combretastatina. |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| KR101925436B1 (ko) | 2008-04-10 | 2018-12-05 | 버지니아 커먼웰스 유니버시티 | 암 치료를 위한 종양 저 산소 상태의 유도 |
-
2009
- 2009-04-08 KR KR1020107025113A patent/KR101925436B1/ko active Active
- 2009-04-08 CN CN200980102782.7A patent/CN102026634B/zh active Active
- 2009-04-08 WO PCT/US2009/039899 patent/WO2009126705A2/en not_active Ceased
- 2009-04-08 JP JP2011504152A patent/JP5731372B2/ja active Active
- 2009-04-08 CN CN201310699012.3A patent/CN104043125B/zh active Active
- 2009-04-08 US US12/922,658 patent/US8591921B2/en active Active
- 2009-04-09 TW TW098111832A patent/TWI504391B/zh active
-
2013
- 2013-10-01 US US14/043,661 patent/US9649316B2/en active Active
-
2015
- 2015-01-07 JP JP2015001834A patent/JP5944018B2/ja active Active
-
2017
- 2017-04-05 US US15/480,250 patent/US10426779B2/en active Active
- 2017-04-05 US US15/480,242 patent/US10159676B2/en active Active - Reinstated
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516565A5 (enExample) | ||
| CN104043125B (zh) | 诱导肿瘤缺氧以治疗癌症 | |
| CY1119001T1 (el) | Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για ανευ νοηματος καταστολη και τη θεραπεια ασθενειας | |
| JP2019507179A5 (enExample) | ||
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| RU2420522C2 (ru) | Новый класс ингибиторов гистондеацетилаз | |
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| AU751701B2 (en) | Ace inhibitor-MMP inhibitor combinations | |
| JP2013513612A5 (enExample) | ||
| JP2012519694A5 (enExample) | ||
| JP2010526840A5 (enExample) | ||
| JP2017530983A5 (enExample) | ||
| JP2008531479A5 (enExample) | ||
| JP2008521827A5 (enExample) | ||
| AR080472A1 (es) | Terapias de inhibidor de autofagia basado en tioxantona para tratar el cancer | |
| RU2012158142A (ru) | Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации | |
| JP2009538276A5 (enExample) | ||
| CY1112637T1 (el) | Παραγων για την προληψη και αγωγη των παθησεων του ηπατος περιεχοντας παραγωγο πυραζολοπυριμιδινης | |
| JP2015131865A (ja) | 抗癌用医薬 | |
| JP2017512211A5 (enExample) | ||
| ES2337848T3 (es) | Formulaciones de valsartan. | |
| MX2024008170A (es) | Tratamiento de trastornos cardiopulmonares | |
| CL2024001520A1 (es) | Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales | |
| CN115803328A (zh) | 哌嗪-2,3-二酮衍生物及其在医药上的应用 | |
| JPWO2020080979A5 (enExample) |